Massachusetts Financial Services Co. MA Sells 89,591 Shares of Cencora, Inc. $COR

Massachusetts Financial Services Co. MA lowered its holdings in Cencora, Inc. (NYSE:COR) by 13.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 568,119 shares of the company’s stock after selling 89,591 shares during the period. Massachusetts Financial Services Co. MA owned approximately 0.29% of Cencora worth $191,882,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. IAG Wealth Partners LLC bought a new stake in shares of Cencora during the 3rd quarter worth approximately $30,000. Cloud Capital Management LLC bought a new position in Cencora in the 3rd quarter valued at approximately $31,000. Caitlin John LLC bought a new position in Cencora in the 3rd quarter valued at approximately $31,000. Westside Investment Management Inc. lifted its stake in Cencora by 200.0% in the 3rd quarter. Westside Investment Management Inc. now owns 105 shares of the company’s stock valued at $33,000 after purchasing an additional 70 shares during the last quarter. Finally, Harbor Investment Advisory LLC bought a new position in Cencora in the 4th quarter valued at approximately $35,000. Institutional investors own 97.52% of the company’s stock.

Cencora Trading Up 0.0%

Shares of NYSE COR opened at $320.97 on Monday. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. Cencora, Inc. has a 52-week low of $271.00 and a 52-week high of $377.54. The firm has a 50 day moving average price of $345.36 and a two-hundred day moving average price of $342.83. The stock has a market cap of $62.44 billion, a P/E ratio of 38.58, a price-to-earnings-growth ratio of 1.50 and a beta of 0.72.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The firm had revenue of $85.93 billion during the quarter, compared to analysts’ expectations of $86.12 billion. During the same period in the prior year, the company posted $3.73 EPS. The company’s revenue was up 5.5% on a year-over-year basis. As a group, equities analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date was Friday, February 13th. Cencora’s dividend payout ratio is 28.85%.

Insider Transactions at Cencora

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total value of $1,807,704.08. Following the completion of the transaction, the chief executive officer directly owned 66,726 shares in the company, valued at approximately $23,669,713.98. This represents a 7.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.38% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on COR. Wells Fargo & Company increased their price objective on shares of Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a research note on Tuesday, February 10th. Robert W. Baird set a $415.00 price objective on shares of Cencora in a research note on Tuesday, January 13th. Barclays increased their price objective on shares of Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a research note on Friday, February 13th. Evercore set a $360.00 price objective on shares of Cencora in a research note on Wednesday. Finally, Leerink Partners reissued an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. Twelve analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $398.17.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.